Neoadjuvant Window Studies of Metformin and Biomarker Development for Drugs Targeting Cancer Metabolism.

Abstract

There has been growing interest in the potential of the altered metabolic state typical of cancer cells as a drug target. The antidiabetes drug, metformin, is now under intense investigation as a safe method to modify cancer metabolism. Several studies have used window of opportunity in breast cancer patients before neoadjuvant chemotherapy to correlate gene expression analysis, metabolomics, immunohistochemical markers, and metabolic serum markers with those likely to benefit. We review the role metabolite measurement, functional imaging and gene sequencing analysis play in elucidating the effects of metabolically targeted drugs in cancer treatment and determining patient selection.

• Authors: Simon R Lord, Neel Patel, Dan Liu, John Fenwick, Fergus Gleeson, Francesca Buffa, Adrian L Harris
• Journal: Journal of the National Cancer Institute. Monographs (J Natl Cancer Inst Monogr) Vol. 2015 Issue 51 Pg. 81-6 (May 2015) ISSN: 1745-6614 [Electronic] United States
• PMID: 26063894 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
• Copyright: © The Author 2015. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: [email protected].

Chemical References

• Biomarkers, Tumor
• Hypoglycemic Agents
• Metformin

Topics

• Biomarkers, Tumor (genetics, metabolism)
• Breast Neoplasms (drug therapy, genetics, metabolism)
• Chemotherapy, Adjuvant (methods)
• Female
• Humans
• Hypoglycemic Agents (therapeutic use)
• Metabolome (drug effects)
• Metformin (therapeutic use)
• Neoadjuvant Therapy (methods)
• Transcriptome (drug effects)